Author:
Montes Maria Luisa,Pulido Federico,Barros Carlos,Condes Emilia,Rubio Rafael,Cepeda Concepción,Dronda Fernando,Antela Antonio,Sanz José,Navas Enrique,Miralles Pilar,Berenguer Juan,Pérez Susana,Zapata Angeles,González-García Juan J.,Peña Jose Ma,Vázquez J. J.,Arribas Jose R.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference11 articles.
1. Panel on Clinical Practices for the Treatment of HIV Infection. (2004). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Foundation, 29 October 2004. http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.pdf (7 January 2005, date last accessed).
2. Walmsley, S., Bernstein, B., King, M. et al. (2002). Lopinavir/ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine346, 2039–46.
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association285, 2486–97.
4. Kinosain, B., Glick, H. & Garland, G. (1994). Cholesterol and coronary heart disease: prediciting risks by levels and ratios. Annals of Internal Medicine121, 641–7.
5. Martínez, E., Domingo, P., Galindo, M. J. et al. (2004). Risk of metabolic abnormalities in HIV-infected patients receiving antirretroviral therapy that contain lopinavir/ritonavir. Clinical Infectious Diseases38, 1017–23.
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献